Literature DB >> 17320178

Reactivation of Graves' orbitopathy after rehabilitative orbital decompression.

Lelio Baldeschi1, Antonella Lupetti, Phung Vu, Iris M M J Wakelkamp, Mark F Prummel, Wilmar M Wiersinga.   

Abstract

OBJECTIVE: To present and discuss three cases of apparent reactivation of Graves' orbitopathy (GO) after orbital decompression and to evaluate the incidence of this phenomenon.
DESIGN: Observational case series and retrospective follow-up study. PARTICIPANTS: A few weeks after surgery 2 patients with GO (patients 1 and 2), treated at our institution with rehabilitative bony orbital decompression during the static phase of the disease showed clinical and radiologic evidence of reactivated orbitopathy. After this observation, a sample of 249 patients who had consecutively undergone the same treatment for the same reason before the second of the 2 observed patients was selected for this study.
METHODS: The records of the selected patients were retrospectively reviewed searching for cases presenting with clinical and radiologic evidence of GO reactivated as a consequence of any type of bony orbital decompression. Patients treated with perioperative systemic glucocorticoids or who had concurrent periorbital diseases, injuries, or surgeries, or who had immunocompromised conditions or a follow-up of < or =2 months, were excluded. MAIN OUTCOME MEASURES: Incidence of reactivation. Clinical history, clinical and radiologic characteristics, treatment modalities, and time course of the reactivation in patients presenting with this phenomenon.
RESULTS: Decompression surgery took place between 1994 and 2000. Eleven patients were excluded for having been treated with perioperative glucocorticoids. Only 1 patient (patient 3) presented with reactivation. The incidence of the phenomenon that we regard as reactivation of GO after rehabilitative bony orbital decompression was therefore 1.3% (3/239). In all 3 patients, the reactivation took place a few weeks after surgery, after an early normal convalescence period and could be controlled with systemic immunosuppression or orbital radiotherapy. None of the patients we report developed further episodes of reactivation during the follow-up period (mean, 7.5 years).
CONCLUSIONS: Based on its clinical characteristics, we suggest naming our observation delayed decompression-related reactivation and we propose using its acronym DDRR when referring to it. Although DDRR appears to be a rare event, it is important for physicians and patients to be aware of its possible occurrence with rehabilitative decompression surgery.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17320178     DOI: 10.1016/j.ophtha.2006.10.036

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  15 in total

Review 1.  Graves orbitopathy: a perspective.

Authors:  Petros Perros; Gerasimos E Krassas
Journal:  Nat Rev Endocrinol       Date:  2009-06       Impact factor: 43.330

2.  Ocular changes and approaches of ophthalmopathy in basedow - graves- parry- flajani disease.

Authors:  George Saraci; Anamaria Treta
Journal:  Maedica (Buchar)       Date:  2011-04

3.  Preoperative clinical features of reactivated of Graves' orbitopathy after orbital decompression.

Authors:  Y J Woo; J W Kim; J S Yoon
Journal:  Eye (Lond)       Date:  2017-01-06       Impact factor: 3.775

4.  Is Recombinant Human TSH a Trigger for Graves' Orbitopathy?

Authors:  C Daumerie; A Boschi; P Perros
Journal:  Eur Thyroid J       Date:  2012-06-07

Review 5.  IGF1 receptor and thyroid-associated ophthalmopathy.

Authors:  Michelle Mohyi; Terry J Smith
Journal:  J Mol Endocrinol       Date:  2017-12-22       Impact factor: 5.098

6.  Teprotumumab for Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; George J Kahaly; Daniel G Ezra; James C Fleming; Roger A Dailey; Rosa A Tang; Gerald J Harris; Alessandro Antonelli; Mario Salvi; Robert A Goldberg; James W Gigantelli; Steven M Couch; Erin M Shriver; Brent R Hayek; Eric M Hink; Richard M Woodward; Kathleen Gabriel; Guido Magni; Raymond S Douglas
Journal:  N Engl J Med       Date:  2017-05-04       Impact factor: 91.245

7.  Compressive Optic Neuropathy and Repeat Orbital Decompression: A Case Series.

Authors:  Courtney Y Kauh; Shivani Gupta; Raymond S Douglas; Victor M Elner; Christine C Nelson; Leslie M Niziol; Alon Kahana
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2015 Sep-Oct       Impact factor: 1.746

8.  Teprotumumab Treatment for Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith
Journal:  Eur Thyroid J       Date:  2020-07-13

9.  Customized Orbital Decompression Surgery Combined with Eyelid Surgery or Strabismus Surgery in Mild to Moderate Thyroid-associated Ophthalmopathy.

Authors:  Seung Woo Choi; Jae Yeun Lee; Helen Lew
Journal:  Korean J Ophthalmol       Date:  2016-01-21

10.  Unilateral proptosis in thyroid eye disease with subsequent contralateral involvement: retrospective follow-up study.

Authors:  Diego Strianese; Raffaele Piscopo; Andrea Elefante; Manuela Napoli; Chiara Comune; Immacolata Baronissi; Raffaele Liuzzi; Mariantonia Ferrara; Alessia D'alessandro; Pasquale Ruggiero; Pasquale Napolitano; Piergiacomo Grassi; Adriana Iuliano; Carmela Russo; Arturo Brunetti; Giulio Bonavolontà
Journal:  BMC Ophthalmol       Date:  2013-05-30       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.